Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening
- PMID: 38492072
- DOI: 10.1007/s00345-024-04905-6
Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening
Comment on
-
PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions.World J Urol. 2024 Feb 16;42(1):84. doi: 10.1007/s00345-024-04776-x. World J Urol. 2024. PMID: 38363332 Free PMC article.
References
-
- Kwe J, Baunacke M, Boehm K, Platzek I, Thomas C, Borkowetz A (2024) PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions. World J Urol 42(1):84. https://doi.org/10.1007/s00345-024-04776-x - DOI - PubMed - PMC
-
- Young RH, Eble JN (2019) The history of urologic pathology: an overview. Histopathology 74(1):184–212. https://doi.org/10.1111/his.13753 - DOI - PubMed
-
- Epstein JI, Allsbrook WC, Amin MB, Egevad LL (2005) ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9):1228–1242. https://doi.org/10.1097/01.pas.0000173646.99337.b1 - DOI - PubMed
-
- Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: a systematic evidence review for the U.S. preventive services task force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17–05229-EF-1.
-
- Catalona WJ (2018) Prostate cancer screening. Med Clin North Am 102(2):199–214. https://doi.org/10.1016/j.mcna.2017.11.001 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous